HEALTHCARE

20 Jun 2017

First-Ever World Kidney Cancer Q&A Day Highlights Growing Global Burden

(ME NewsWire)-- Kidney cancer is a silent disease that’s on the rise. The global incidence of kidney cancer is predicted to increase by a shocking 22 percent by 2020. Explanations are incomplete, but include risk factors such as aging, obesity,"...

Continue Reading

20 Jun 2017

New Study Compares Performance of Masimo Next Generation SedLine® Patient State Index (PSi) to Original PSi During Anesthesia

(ME NewsWire)-- Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at Euroanaesthesia 2017 in Geneva, Switzerland. In the study, researchers at University Medical Center Groningen, Netherlands, compared original and Next Generation versions of Masimo Patient State Index (PSi, a processed EEG parameter related to the effect of anesthetic agents) during Masimo SedLine® brain function monitoring of patients under propofol and sevoflurane anesthesia.1 SedLine brain function monitoring features four simultaneous EEG leads to enable continuous assessment of both sides of the brain, four EEG waveforms, a Density Spectral......

Continue Reading

13 Jun 2017

Egypt donates food, medical aid to South Sudan

Egypt has transported humanitarian aid to South Sudan to reduce the suffering of civilians caught up in the ongoing civil war in the world’s youngest nation on Monday.

The humanitarian aid was shipped to"...

Continue Reading

12 Jun 2017

Kieran Murphy Appointed CEO of GE Healthcare, Succeeding John Flannery

(ME NewsWire)-- GE Chairman and CEO Jeff Immelt announced today the appointment of Kieran Murphy as president and CEO of GE Healthcare, effective immediately. Murphy is currently president and CEO of GE Healthcare Life Sciences. Murphy succeeds"...

Continue Reading

12 Jun 2017

New Study Investigates the Clinical Utility of ORi™, Masimo Oxygen Reserve Index™

(ME NewsWire)-- Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at the recent International Anesthesia Research Society (IARS) Annual Meeting in Washington, DC. In the study, researchers at the UC Davis School of Medicine evaluated the potential clinical utility of Masimo Oxygen Reserve Index™ (ORi™) as an early warning of arterial hemoglobin desaturation in critically ill patients.1 ORi is a relative indicator of the partial pressure of oxygen in arterial blood (PaO2) in the range of 100 to 200 mmHg. ORi is intended to supplement, not replace, oxygen saturation (SpO2) monitoring and PaO2 measurements.......

Continue Reading

09 Jun 2017

‘Project Last Mile’ Expands to Liberia and Swaziland, Strengthening Health Systems across Africa 

(ME NewsWire)-- Today at the European Development Days, The Coca-Cola Company and its Foundations, in partnership with The Global Fund to Fight AIDS, Tuberculosis and Malaria, the U.S. Agency for International Development and the Bill & Melinda"...

Continue Reading

08 Jun 2017

Julphar Brings Dandasha to UAE

The Emirati pharmaceutical company Julphar Gulf Pharmaceutical Industries, one of the key players in the region, has launched a new drug – Dandasha – in the UAE market to treat erectile dysfunction (ED) in adult men.

Marketed"...

Continue Reading

08 Jun 2017

Updated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation

40.3% Overall Response Rate (ORR) with Median Duration of Response of 5.8 Months and 19.3% Complete Response (CR) Rate with Median Duration of Response of 8.8 Months in Patients With a CR

Overall Safety Profile was Consistent with Previously Reported Data

Simultaneous"...

Continue Reading

07 Jun 2017

Takeda and Seattle Genetics Announce Lancet Publication of Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma

(ME NewsWire)-- Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the randomized Phase 3 ALCANZA clinical trial evaluating ADCETRIS (brentuximab vedotin) in patients with cutaneous T-cell lymphoma (CTCL) were published in the journal Lancet. Data were previously presented in an oral session at the 58th American Society of Hematology (ASH) annual meeting in December 2016. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30 which is expressed on CTCL lesions in approximately 50 percent of patients with the disease. ADCETRIS is currently not approved for the treatment......

Continue Reading

06 Jun 2017

AstraZeneca Presents Tagrisso (osimertinib) Data in Patients with EGFR T790M-Mutation Positive Lung Cancer and Central Nervous System Metastases 

Evidence of activity in patients with EGFR mutation-positive NSCLC and leptomeningeal metastases from the BLOOM trial (ME NewsWire)-- AstraZeneca today reported further evidence that Tagrisso (osimertinib), the potential new standard of care for adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), also shows efficacy in those patients with disease progression to central nervous system (CNS) metastases.1 The data, presented at the 2017 American......

Continue Reading
Found articles: - Pages  
Contact US | Powered by CNPHUB.com - All Rights Reserved